GenVec yesterday announced it suspended a trial of its TNFerade cancer treatment after one of the trial participants died, even though a link between the drug and the death has not been proven. Eight trial participants with esophageal cancer were being treated with high doses of the drug in combination with radiation and three of them developed blood clots. One of the three died and the case was "potentially related" to the drug, according to a study summary. "We want to make sure there is not a pattern here we should be concerned about," GenVec's CEO said. "Our first and foremost concern is always patient safety."